Browse by author
Lookup NU author(s): Dr Renae StefanettiORCiD, Dr Alasdair Blain, Dr Cecilia Jimenez Moreno, Linda Errington, Dr Yi NgORCiD, Professor Bobby McFarlandORCiD, Emeritus Professor Doug Turnbull, Jane Newman, Professor Grainne Gorman
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2020 Stefanetti RJ et al.Background: The benefit and safety of exercise training for patients with neuromuscular disorders (NMDs) has long been a contentious topic. This is, in part, due to recognised challenges associated with rare diseases including small and heterogenous patient populations. We performed a systematic review and meta-analyses to evaluate the effectiveness and safety of interventional exercise and establish minimal clinically important differences (MCID) in outcomes to facilitate clinical interpretation. Methods: We searched six databases from inception to Mar 2018. Aerobic, strength, and combined (aerobic and strength) intervention were eligible. Meta-analyses compared outcomes at baseline with those after at least six weeks (before-after exercise within individuals). A further meta-analysis compared outcomes before-after exercise between groups (exercise training versus usual care). Disease heterogeneity was explored using a random effect model. This study was registered (PROSPERO, CRD42018102183). An interactive database was developed to facilitate full interrogations of data. Results: We identified 130 articles describing 1,805 participants with 35 different forms of NMD. Of these studies, 76 were suitable for meta-analyses. Within group and between group meta-analyses detected an increase in peak aerobic capacity (p=0.04), and peak power (p=0.01). Six-minute walk test (p=0.04), sit-to-stand (STS) (repetitions) (p=0.03), STS (seconds) (p=0.04), rise from supine (p=0.008), SF-36 (p=0.0003), fatigue severity (p=<0.0001), citrate synthase (p=0.0002), central nuclei (p=0.04), type 1 (p=0.002) and type II muscle fibre area (p=0.003), were only able to detect change within group meta-analyses. Substantial I 2 statistic heterogeneity was revealed for STS (seconds) ( I2=58.5%; p=0.04) and citrate synthase ( I2=70.90%; p=0.002), otherwise heterogeneity for all outcomes was low. No study-related serious adverse events were reported nor significant increases in creatine kinase. Conclusions: Exercise training in patients with NMDs appears to cause no harm across a range of outcomes. With the emergence of new therapeutic strategies, defining MCID is vital in informing future clinical trial design.
Author(s): Stefanetti RJ, Blain A, Jimenez-Moreno C, Errington L, Ng YS, McFarland R, Turnbull DM, Newman J, Gorman GS
Publication type: Review
Publication status: Published
Journal: Wellcome Open Research
Year: 2020
Volume: 5
Issue: 84
Online publication date: 04/05/2020
Acceptance date: 02/04/2016
ISSN (electronic): 2398-502X
Publisher: F1000 Research Ltd
URL: https://doi.org/10.12688/wellcomeopenres.15825.1
DOI: 10.12688/wellcomeopenres.15825.1
